- Home
- YJ vs MBIO Comparison
YJ vs MBIO Comparison
Compare YJ & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YJ
- MBIO
- Stock Information
- Founded
- YJ 2015
- MBIO 2015
- Country
- YJ China
- MBIO United States
- Employees
- YJ N/A
- MBIO N/A
- Industry
- YJ Other Specialty Stores
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- YJ Consumer Discretionary
- MBIO Health Care
- Exchange
- YJ Nasdaq
- MBIO Nasdaq
- Market Cap
- YJ 8.1M
- MBIO 7.3M
- IPO Year
- YJ 2019
- MBIO N/A
- Fundamental
- Price
- YJ $1.74
- MBIO $4.17
- Analyst Decision
- YJ
- MBIO Strong Buy
- Analyst Count
- YJ 0
- MBIO 1
- Target Price
- YJ N/A
- MBIO $2.00
- AVG Volume (30 Days)
- YJ 220.1K
- MBIO 478.1K
- Earning Date
- YJ 11-21-2024
- MBIO 03-10-2025
- Dividend Yield
- YJ N/A
- MBIO N/A
- EPS Growth
- YJ N/A
- MBIO N/A
- EPS
- YJ N/A
- MBIO N/A
- Revenue
- YJ $66,957,730.00
- MBIO N/A
- Revenue This Year
- YJ N/A
- MBIO N/A
- Revenue Next Year
- YJ N/A
- MBIO N/A
- P/E Ratio
- YJ N/A
- MBIO N/A
- Revenue Growth
- YJ N/A
- MBIO N/A
- 52 Week Low
- YJ $1.42
- MBIO $3.72
- 52 Week High
- YJ $4.72
- MBIO $76.00
- Technical
- Relative Strength Index (RSI)
- YJ 51.64
- MBIO 27.51
- Support Level
- YJ $1.56
- MBIO $9.65
- Resistance Level
- YJ $1.79
- MBIO $13.30
- Average True Range (ATR)
- YJ 0.13
- MBIO 2.34
- MACD
- YJ 0.00
- MBIO -0.65
- Stochastic Oscillator
- YJ 64.29
- MBIO 2.47
About YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in China.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.